Last reviewed · How we verify
HMBD-001 and enzalutamide — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HMBD-001 and enzalutamide (HMBD-001 and enzalutamide) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HMBD-001 and enzalutamide TARGET | HMBD-001 and enzalutamide | Cancer Research UK | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HMBD-001 and enzalutamide CI watch — RSS
- HMBD-001 and enzalutamide CI watch — Atom
- HMBD-001 and enzalutamide CI watch — JSON
- HMBD-001 and enzalutamide alone — RSS
Cite this brief
Drug Landscape (2026). HMBD-001 and enzalutamide — Competitive Intelligence Brief. https://druglandscape.com/ci/hmbd-001-and-enzalutamide. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab